Objective To investigate whether oestrogens can be used as treatment to diminish disease activity in women with rheumatoid arthritis. Methods-Forty postmenopausal female patients with active rheumatoid arthritis participated in a placebo-controlled, double-blind study on the possible beneficial effect of adjuvant treatment of oestradiol on disease activity. Results-Thirty three patients completed 52 weeks of treatment with 2 mg oestradiolvalerate or placebo. No statistically significant difference was found in and between both treatment groups with regard to articular indices, pain score by visual analogue scale, erythrocyte sedimentation rate and health questionnaire on daily activities before, during and at the end of the study. Conclusion-This first randomised prospective placebo-controlled study shows no beneficial effect of oestrogens on disease activity in postmenopausal female patients with rheumatoid arthritis.
Epidemiological and immunological data suggest that female hormones may play a role in the aetiology and course of rheumatoid arthritis (RA). There is a clear female to male preponderance of the disease.' In women the use of oral contraceptives may protect against development of RA or reduce the severity of the disease.2 3 Disease symptoms are generally less in the second half of the menstrual cycle when sex steroid levels are high,4 whereas the risk of developing the disease is highest at the age of the menopause. 5 During pregnancy there is often a decrease in disease activity of RA, with a flare up in the weeks after delivery. 6 In animal models adjuvant oestrogens have been shown to suppress collagen induced arthritis.7 Most circumstantial data until now suggest a beneficial effect of oestrogens on disease activity.'
A few small uncontrolled studies have investigated possible therapeutic effects of sex hormones on human disease, with conflicting results.9-1" Recently two small studies, with a different design have been reported. One of them reported some, and the other no beneficial effect of oestrogens on disease activity in women with RA.2 13 To investigate the possible beneficial effects of oestrogens on disease activity, we conducted a double-blind placebo-controlled study lasting one year in forty postmenopausal female patients with RA.
Patients and methods Patients Forty postmenopausal female patients with adult onset RA were admitted to the study; no contraindication for oestrogen treatment was found in any of the patients. Patients were considered to be postmenopausal when there had been no menstruation in the previous year. Patients using corticosteroids or hormonal replacement therapy were not allowed to participate in the study. All patients fulfilled the reviewed criteria for RA'4 and had active disease defined by at least 3 of the following criteria: a) more than 6 painful joints; b) more than 3 swollen joints; c) erythrocyte sedimentation rate >28 mm/lh; d) morning stiffness >45 minutes. When patients used disease modifying anti-rheumatic drugs (DMARD), these were used in a constant dose for at least three months before the start of the study and the dose of these drugs was kept stable during the study.
Study design
The trial was a double-blind controlled study comparing the additional effect of 2 mg oestradiolvalerate (ProgynovaR) In conclusion, no clear beneficial effect of adjuvant therapy with oestradiolvalerate on disease activity in postmenopausal patients with RA was seen in this placebo-controlled double-blind study. Our results show that there is no place for the therapeutic use of adjuvant oestrogens to diminish disease activity of RA. This treatment, however, may improve bone mineral density in these 23 patients.
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